Insider · CIK 0001914847

Aziz Kabeer

Reports to the SEC for 1 company · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001914847

Forms 4 and 5

Insider transactions

48 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-12	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+2,465 sh	—	—	61,571
2026-07-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+2,852 sh	—	—	59,106
2026-04-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+3,775 sh	—	—	56,254
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20.7K sh	—	—	20,724
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20.7K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.7K sh	—	—	23,742
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−23.7K sh	—	—	0
2026-02-20	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.4K sh	—	—	20,400
2026-01-12	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+11.6K sh	—	—	52,479
2025-10-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+10.4K sh	—	—	40,919
2025-07-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+11.9K sh	—	—	30,552
2025-05-22	ANTXAN2 Therapeutics, Inc. · Stock Optin (Right to Buy)A Award	Director	AAward	+19.1K sh	—	—	19,111
2025-04-10	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+9,705 sh	—	—	18,677
2024-12-19	ANTXAN2 Therapeutics, Inc.A Award	Director	AAward	+8,972 sh	—	—	8,972
2024-06-19	ANTXAN2 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+64.5K sh	—	—	64,503
2024-01-16	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−84.1K sh	$19.65	−$1.65M	1,995,958
2024-01-16	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−15.9K sh	$19.65	−$313K	377,542
2023-11-14	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−1,522 sh	$16.15	−$24.6K	2,080,051
2023-11-14	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−288 sh	$16.15	−$4,650.048	393,449
2023-10-02	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−4,770 sh	$16.07	−$76.7K	2,081,573
2023-10-02	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−902 sh	$16.07	−$14.5K	393,737
2023-09-29	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−83.3K sh	$16.28	−$1.36M	2,086,343
2023-09-29	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−15.8K sh	$16.28	−$257K	394,639
2023-09-28	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−7,160 sh	$16.11	−$115K	2,169,680
2023-09-28	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−1,356 sh	$16.11	−$21.8K	410,403
2023-09-27	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−707 sh	$16.07	−$11.4K	2,176,840
2023-09-27	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−134 sh	$16.07	−$2,153.38	411,759
2023-09-13	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−336 sh	$16.00	−$5,376	2,177,547
2023-09-13	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−64 sh	$16.00	−$1,024	411,893
2023-09-07	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−2,841 sh	$16.05	−$45.6K	2,177,883
2023-09-07	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−537 sh	$16.05	−$8,618.85	411,957
2023-09-06	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−3,164 sh	$16.02	−$50.7K	2,180,724
2023-09-06	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−598 sh	$16.02	−$9,579.96	412,494
2023-08-23	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−336 sh	$16.00	−$5,376	2,183,888
2023-08-23	ANTXAN2 Therapeutics, Inc.S Sale	Director	SSale	−64 sh	$16.00	−$1,024	413,092
2023-06-07	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.7K sh	—	—	23,742
2022-06-06	ANTXAN2 Therapeutics, Inc.J Other	Director	JOther	−26.5K sh	$15.00	−$398K	2,184,224
2022-06-06	ANTXAN2 Therapeutics, Inc.J Other	Director	JOther	+26.5K sh	$15.00	+$398K	413,156
2022-05-12	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20.7K sh	—	—	20,724
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	Director	CConversion	+1.65M sh	—	—	1,651,636
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	Director	CConversion	+312K sh	—	—	312,415
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	Director	CConversion	+392K sh	—	—	2,044,069
2022-03-29	ANTXAN2 Therapeutics, Inc.C Conversion	Director	CConversion	+74.2K sh	—	—	386,645
2022-03-29	ANTXAN2 Therapeutics, Inc.P Purchase	Director	PPurchase	+167K sh	$15.00	+$2.5M	2,210,735
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	Director	CConversion	−1.65M sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series A Convertible Preferred StockC Conversion	Director	CConversion	−312K sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	Director	CConversion	−392K sh	—	—	0
2022-03-29	ANTXAN2 Therapeutics, Inc. · Series B Convertible Preferred StockC Conversion	Director	CConversion	−74.2K sh	—	—	0

Recent filings

Accepted (ET)
Oct 134
Aziz Kabeer0001193125-26-420639
SEC(opens sec.gov)
Jul 104
Aziz Kabeer0001193125-26-301167
SEC(opens sec.gov)
Apr 104
Aziz Kabeer0001193125-26-151632
SEC(opens sec.gov)
Mar 234
Aziz Kabeer0001193125-26-120226
SEC(opens sec.gov)
Feb 234
Aziz Kabeer0001193125-26-064059
SEC(opens sec.gov)
Jan 144
Aziz Kabeer0001193125-26-013041
SEC(opens sec.gov)
Oct 144
Aziz Kabeer0001193125-25-238983
SEC(opens sec.gov)
Jul 114
Aziz Kabeer0000950170-25-095408
SEC(opens sec.gov)
May 234
Aziz Kabeer0000950170-25-077035
SEC(opens sec.gov)
Apr 114
Aziz Kabeer0000950170-25-053367
SEC(opens sec.gov)
Dec 234
Aziz Kabeer0000950170-24-139800
SEC(opens sec.gov)
Jun 214
Aziz Kabeer0000950170-24-076404
SEC(opens sec.gov)
Jan 184
Aziz Kabeer0000950170-24-005515
SEC(opens sec.gov)
Nov 164
Aziz Kabeer0000950170-23-064609
SEC(opens sec.gov)
Oct 34
Aziz Kabeer0000950170-23-051733
SEC(opens sec.gov)

Companies

AN2 Therapeutics, Inc.DirectorANTX

Address

C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100

MENLO PARK, CA, 94025